Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894590 | 1.00 | NR1H4 (0.58) | NR1H4ALOX5ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL5612012 | 0.85 | KMT2A (0.49) | NR1H4ALDH1A1L3MBTL1LMNA | |
| SCHEMBL5612021 | 0.85 | KMT2A (0.49) | NR1H4ALDH1A1L3MBTL1LMNA | |
| SCHEMBL5349028 | 0.81 | NR1H4 (0.64) | NR1H4ALOX5ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL8235784 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1LMNA | |
| SCHEMBL8242231 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1LMNA | |
| SCHEMBL5300752 | 0.79 | ALOX5 (0.61) | NR1H4ALOX5ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL1203178 | 0.78 | ALOX5 (0.67) | NR1H4ALOX5ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL27619575 | 0.78 | MEN1 (0.50) | NR1H4ALDH1A1L3MBTL1 | |
| SCHEMBL28711047 | 0.77 | ALDH1A1 (0.50) | ALOX5ALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879997-B2 | Tumor necrosis factor-alpha converting enzyme inhibitors such as (2S,3R)-4-oxo-3-[[4-[(2-phenylquinolin-4-yl)methoxy]phenyl]methyl]azetidine-2-carboxylic acid, useful for the treatment of diseases or conditions mediated by matrix Metalloproteinases and tumor necrosis factor-alpha | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20070191332-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191332-A1 | Compounds for the treatment of inflammatory disorders | TNF, MMP8, MPO | NR1H4 349/4885ALOX5 536/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.